We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Shattuck Labs Inc is a clinical-stage biotechnology company pioneering the development of dual-sided fusion proteins as an entirely new class of biologic medicine. Its product candidate, SL-172154, has been rationally designed to simultaneously inhibit the CD47/SIRPa checkpoint interaction to restor... Shattuck Labs Inc is a clinical-stage biotechnology company pioneering the development of dual-sided fusion proteins as an entirely new class of biologic medicine. Its product candidate, SL-172154, has been rationally designed to simultaneously inhibit the CD47/SIRPa checkpoint interaction to restore an anti-tumor immune response and to activate the CD40 costimulatory receptor to bolster an immune response. Its product candidate, SL-279252, which is being developed in collaboration with Takeda Pharmaceuticals, or Takeda, has been rationally designed to simultaneously inhibit the PD-1/PD-L1 interaction and activate the OX40 receptor. Show more
– Announced development of SL-325, a first-in-class antagonist antibody to DR3, the receptor for TL1A; IND filing expected in Q3'2025 – – Cash balance of approximately $90M as of September 30...
– Interim clinical data for SL-172154 in combination with azacitidine in TP53 mutant (TP53m) acute myeloid leukemia (AML) and higher-risk myelodysplastic syndromes (HR-MDS) showed only modest...
– Announced updated positive interim data from the Phase 1B dose-expansion clinical trial of SL-172154 in combination with Azacitidine (AZA) in frontline Higher-Risk Myelodysplastic Syndromes...
AUSTIN, TX and DURHAM, NC, July 30, 2024 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.175 | -14.4628099174 | 1.21 | 1.56 | 1.03 | 312755 | 1.23991145 | CS |
4 | -0.265 | -20.3846153846 | 1.3 | 1.56 | 1.03 | 332806 | 1.24851917 | CS |
12 | -2.435 | -70.1729106628 | 3.47 | 3.95 | 1.03 | 599600 | 1.69667852 | CS |
26 | -6.485 | -86.2367021277 | 7.52 | 7.825 | 1.03 | 487770 | 2.8822525 | CS |
52 | -1.185 | -53.3783783784 | 2.22 | 11.76 | 1.03 | 759710 | 5.38304878 | CS |
156 | -8.405 | -89.0360169492 | 9.44 | 11.76 | 1.03 | 331633 | 5.25602462 | CS |
260 | -17.575 | -94.4384739387 | 18.61 | 60.5162 | 1.03 | 296167 | 9.4032396 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions